Sharp Brains: Brain Fitness and Cognitive Health News

Neuroplasticity, Brain Fitness and Cognitive Health News


An idea gaining traction: Can measuring typing cadence help monitor and treat Parkinson’s Disease?

FDA grants break­through device des­ig­na­tion to Neu­raMetrix (press release):

The U.S. Food and Drug Admin­is­tra­tion (FDA) has grant­ed Break­through Device des­ig­na­tion to the Neu­raMetrix brain health mon­i­tor­ing solu­tion. The des­ig­na­tion is grant­ed for devices “that pro­vide more effec­tive treat­ment or diag­no­sis of life-threat­en­ing or irre­versibly debil­i­tat­ing human dis­ease or con­di­tions”. The approved use is mon­i­tor­ing of Parkinson’s dis­ease (PD) to more effec­tive­ly treat patients with PD, which is a sig­nif­i­cant chal­lenge for neu­rol­o­gists today as they only see the patient a few times a year. 

PD is a debil­i­tat­ing chron­ic con­di­tion that affects hun­dreds of thou­sands of lives glob­al­ly. Although there is no cure for PD, ear­ly detec­tion, dis­ease man­age­ment and prop­er treat­ment can pro­vide sig­nif­i­cant relief. “The break­through device des­ig­na­tion reaf­firms that the Neu­raMetrix brain mon­i­tor­ing solu­tion could enable bet­ter treat­ment of patients by pro­vid­ing more pre­cise and time­ly feed­back,” said Jan Samzelius, chief exec­u­tive offi­cer of Neu­raMetrix.

The Neu­raMetrix’ dig­i­tal bio­mark­er mea­sures incon­sis­ten­cy of typ­ing cadence (the rhythm of how we type on a key­board) — a proven indi­ca­tor of brain health. Clin­i­cal data has demon­strat­ed that Neu­raMetrix may be effec­tive for Cen­tral Ner­vous Sys­tem (CNS) dis­eases such as PD, Alzheimer’s dis­ease (AD) and Depres­sion.”

About the Breakthrough Devices Program

  • Descrip­tion: The Break­through Devices Pro­gram is a vol­un­tary pro­gram for cer­tain med­ical devices and device-led com­bi­na­tion prod­ucts that pro­vide for more effec­tive treat­ment or diag­no­sis of life-threat­en­ing or irre­versibly debil­i­tat­ing dis­eases or con­di­tions … The Break­through Devices Pro­gram replaces the Expe­dit­ed Access Path­way and Pri­or­i­ty Review for med­ical devices. The FDA con­sid­ers devices grant­ed des­ig­na­tion under the Expe­dit­ed Access Path­way to be part of the Break­through Devices Pro­gram.
  • To learn more, vis­it the FDA page Here

News in Context:

Leave a Reply...

Loading Facebook Comments ...

Leave a Reply

Categories: Cognitive Neuroscience, Health & Wellness, Technology

Tags: , , , ,

About SharpBrains

As seen in The New York Times, The Wall Street Journal, BBC News, CNN, Reuters,  SharpBrains is an independent market research firm tracking how brain science can improve our health and our lives.

Search in our archives

Follow us and Engage via…

RSS Feed

Watch All Recordings Now (40+ Speakers, 12+ Hours)